coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recombinant proteins and plasmid DNA for clients across the ...

Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® ...

As U.S. stock markets continue to recover, with major indices closing higher for the third consecutive day, investors are cautiously optimistic about the potential easing of tariffs and its impact on ...

R&D Expenses: Research and development expenses for the year ended December 31, 2024 decreased to approximately $2,044,000 ...

Detailed price information for Protalix Biotherapeutics (PLX-A) from The Globe and Mail including charting and trades.

McGill University researchers have demonstrated that AMPA receptors (AMPARs), which mediate fast excitatory neurotransmission ...

Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to acceler ...

The Central Board of Secondary Education (CBSE) is conducting the Class 12 board exams for the 2025 academic year. The ...

India’s Aditya-L1 captures an unprecedented solar flare, IISc researchers unlock gene activation with mini proteins in yeast, ...

Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, March 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: ...

Transfect the cells with the recombinant vector using Lipofectamine ... Use the cells on the coverslip to check the level of GFP fusion protein expression with high-resolution fluorescence ...